Qian Zhang1,
Hua Yang1,
Caiyi Tang2,
Qian Wang3,
Lili Ren1,
Chao Jia4,
Hui Zou5 
For correspondence:- Hui Zou Email: huizou0051@163.com Tel:+862352663968
Accepted: 30 July 2021 Published: 29 August 2022
Citation: Zhang Q, Yang H, Tang C, Wang Q, Ren L, Jia C, et al. Erratum: FMNL1 promotes growth and metastasis of breast cancer by inhibiting BRCA1 via upregulation of HMGA1. Trop J Pharm Res 2022; 21(8):1807-1807 doi: 10.4314/tjpr.v21i8.31
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
In the earlier published article, “Herbei Province” included in the affiliation of the second author is incorrect. “Chongqing” is a municipality directly under the Central Government and does not belong to "Hebei Province”. At the request of the author, the correct affiliation is provided above. New citation: Zhang Q, Yang H, Tang C, Wang Q, Ren L, Jia C, et al. FMNL1 promotes growth and metastasis of breast cancer by inhibiting BRCA1 via upregulation of HMGA1. Trop J Pharm Res 2021; 20(8):1559-1564 doi: 10.4314/tjpr.v20i8.2. Erratum: 2022; 21(8): 1807 doi: http://dx.doi.org/10.4314/ tjpr.v 21i8.31 Earlier citation: Zhang Q, Yang H, Tang C, Wang Q, Ren L, Jia C, et al. FMNL1 promotes growth and metastasis of breast cancer by inhibiting BRCA1 via upregulation of HMGA1. Trop J Pharm Res 2021; 20(8):1559-1564 doi: 10.4314/tjpr.v20i8.2
Archives
News Updates
Fulltext in PDF